Albemarle Co. (NYSE:ALB) Stock Holdings Lifted by Cwm LLC

Cwm LLC grew its stake in shares of Albemarle Co. (NYSE:ALBGet Rating) by 2.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,185 shares of the specialty chemicals company’s stock after purchasing an additional 47 shares during the quarter. Cwm LLC’s holdings in Albemarle were worth $578,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in ALB. SJS Investment Consulting Inc. bought a new position in Albemarle in the 3rd quarter worth approximately $28,000. Covestor Ltd boosted its stake in Albemarle by 51.2% during the 1st quarter. Covestor Ltd now owns 130 shares of the specialty chemicals company’s stock valued at $29,000 after purchasing an additional 44 shares in the last quarter. Riverview Trust Co boosted its stake in Albemarle by 92.3% during the 2nd quarter. Riverview Trust Co now owns 175 shares of the specialty chemicals company’s stock valued at $37,000 after purchasing an additional 84 shares in the last quarter. CoreCap Advisors LLC bought a new position in Albemarle during the 2nd quarter valued at $39,000. Finally, Eagle Bay Advisors LLC boosted its stake in Albemarle by 122.6% during the 2nd quarter. Eagle Bay Advisors LLC now owns 207 shares of the specialty chemicals company’s stock valued at $43,000 after purchasing an additional 114 shares in the last quarter. 82.24% of the stock is owned by institutional investors.

Insider Buying and Selling at Albemarle

In other Albemarle news, EVP Karen G. Narwold sold 2,250 shares of the company’s stock in a transaction that occurred on Tuesday, November 1st. The shares were sold at an average price of $285.66, for a total value of $642,735.00. Following the completion of the sale, the executive vice president now owns 11,444 shares of the company’s stock, valued at $3,269,093.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Karen G. Narwold sold 2,250 shares of the stock in a transaction on Tuesday, November 1st. The shares were sold at an average price of $285.66, for a total transaction of $642,735.00. Following the completion of the sale, the executive vice president now owns 11,444 shares of the company’s stock, valued at $3,269,093.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott Tozier sold 1,719 shares of the stock in a transaction on Friday, January 6th. The stock was sold at an average price of $220.00, for a total transaction of $378,180.00. Following the sale, the chief financial officer now directly owns 63,384 shares of the company’s stock, valued at approximately $13,944,480. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,681 shares of company stock valued at $5,310,662. Corporate insiders own 0.25% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on ALB. Bank of America increased their price objective on Albemarle from $262.00 to $332.00 and gave the company a “neutral” rating in a research report on Monday, October 3rd. Deutsche Bank Aktiengesellschaft cut their price objective on Albemarle from $325.00 to $290.00 in a research report on Tuesday. Berenberg Bank downgraded Albemarle from a “buy” rating to a “hold” rating and increased their price objective for the company from $260.00 to $270.00 in a research report on Thursday, October 13th. Morgan Stanley increased their price objective on Albemarle from $145.00 to $155.00 and gave the company an “underweight” rating in a research report on Monday, November 28th. Finally, UBS Group reduced their target price on Albemarle from $297.00 to $250.00 and set a “neutral” rating for the company in a report on Wednesday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $288.79.

Albemarle Price Performance

Albemarle stock opened at $236.56 on Thursday. The firm has a market capitalization of $27.71 billion, a P/E ratio of 17.93, a PEG ratio of 0.49 and a beta of 1.45. The business has a 50-day moving average of $257.92 and a 200-day moving average of $256.60. The company has a current ratio of 1.73, a quick ratio of 1.08 and a debt-to-equity ratio of 0.45. Albemarle Co. has a 1 year low of $169.93 and a 1 year high of $334.55.

Albemarle (NYSE:ALBGet Rating) last issued its earnings results on Wednesday, November 2nd. The specialty chemicals company reported $7.50 EPS for the quarter, beating the consensus estimate of $6.84 by $0.66. Albemarle had a net margin of 27.77% and a return on equity of 26.84%. The firm had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the firm earned $1.05 earnings per share. The business’s quarterly revenue was up 151.9% on a year-over-year basis. On average, equities analysts anticipate that Albemarle Co. will post 21.02 EPS for the current year.

Albemarle Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, January 3rd. Shareholders of record on Friday, December 16th were paid a $0.395 dividend. This represents a $1.58 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend was Thursday, December 15th. Albemarle’s payout ratio is presently 11.98%.

About Albemarle

(Get Rating)

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties; and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes in the areas of steroid chemistry and vitamins, life sciences, pharmaceutical industry, and other markets.

Featured Stories

Institutional Ownership by Quarter for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.